| COMP | cartilage oligomeric matrix protein; complication; cyclophosphamide, vincristine, methotrexate, pred... |
|---|---|
| comp | comparative; compensation, compensated; complaint; complete; composition; compound, compounded; comp... |
| HBsAg/adr | hepatitis B surface antigen manifesting group-specific determinant a and subtype-specific determinan... |
| LSP | left sacroposterior [fetal position]; linguistic string project; liver-specific protein; lymphocyte-... |
| SR | sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat... |
| COMP | Cartilage Oligomeric Matrix Protein |
|---|---|
| A.S.I. | Active Specific Immunotherapy |
| ASA | Allele Specific Amplification |
| ASO | Allele specific oligonucleotide |
| AS-PCR | Allele specific polymerase chain reaction |
| 영문 | specific gravity | 한글 | 비중 |
|---|---|---|---|
| 설명 | 단위 부피당 질량. 소변의 비중은 소변의 농도를 반영한다. 예를 들어 소변의 비중이 크면, 콩팥의 물흡수가 원활히 이루어지고 있음을 나타낸다. |
||
| site-specific DNA-methyltransferase (adenine-specific) | <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on adenine residues in a specific short base sequence in the host cell DNA. The enzyme catalyses the methylation of DNA adenine in the presence of s-adenosyl-l-methionine to form DNA containing 6-methylaminopurine and s-adenosyl-l-homocysteine. Registry number: EC 2.1.1.72 (12 Dec 1998) |
|---|---|
| site-specific DNA methyltransferase (cytosine-specific) | <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on cytosine residues in a specific short base sequence in the host cell's DNA. The enzyme catalyses the methylation of DNA cytosine in the presence of s-adenosyl-l-methionine to form s-adenosyl-l-homocysteine and DNA containing 5-methylcytosine. Registry number: EC 2.1.1.73 (12 Dec 1998) |
| aids vaccines | Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent aids. Some vaccines containing antigens are recombinantly produced. (12 Dec 1998) |
| bacterial vaccines | Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. (12 Dec 1998) |
| cancer vaccines | Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumour cells as the source of antigens, or using tumour-specific antigens, often recombinantly produced. (12 Dec 1998) |
| vaccines | Vaccines are microbial preparations of killed or modified microorganisms which can stimulate an immune response in the body in order to prevent future infection with similar microorganism. The smallpox vaccine has totally eliminated the smallpox disease from our planet. (12 Dec 1998) |
| vaccines, attenuated | Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. (12 Dec 1998) |
| vaccines, combined | Two or more vaccines in a single dosage form. (12 Dec 1998) |
| vaccines, conjugate | Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognised by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection. (12 Dec 1998) |
| vaccines, DNA | Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers. (12 Dec 1998) |
| vaccines, inactivated | Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. (12 Dec 1998) |
| vaccines, synthetic | Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. (12 Dec 1998) |
| malaria vaccines | Vaccines made from antigens arising from any of the four strains of plasmodium which cause malaria in humans, or from p. Berghei which causes malaria in rodents. (12 Dec 1998) |
| viral hepatitis vaccines | Any vaccine raised against any virus or viral derivative that causes hepatitis. (12 Dec 1998) |
| viral vaccines | Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
스페시픽디센시타이징백신(캄프리트코오스A) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스B) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스C) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스D) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스E) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스F) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스G) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스H) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스I) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
|
|
스페시픽디센시타이징백신(캄프리트코오스J) - 새창
|
신광신약 |
Allergen 추출물 | 일반의약품 | 비급여 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|